Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07234890Phase 2Recruiting

Study to Evaluate the Effects of AV-001 on HD-induced Brain Injury.

Role: collaborator

NCT05123755Phase 2Recruiting

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

Role: lead

NCT04737486Phase 1Completed

A First-in-Human Study of AV-001 in Healthy Subjects

Role: lead

All 3 trials loaded